Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511

Biological & Pharmaceutical Bulletin
Masako YokooShinya Kimura

Abstract

Long-term treatment with imatinib mesylate (IM) allows patients with chronic myeloid leukemia (CML) to live a near-normal lifespan. However, the fact that tyrosine kinase inhibitors, including IM, are extremely expensive is a major cause of poor adherence, resulting in disease relapse or drug resistance. Therefore, physicians are encouraged to prescribe generic drugs to reduce the financial burden of medical expenses. In Japan, only generic drugs that have a basic chemical structure and pharmacokinetic data that are the same as those of the original drug are approved. However, it is not mandatory to demonstrate that generic drugs have adequate biological effects. This is one of the reasons why Japanese hematologists do not often use generic IM. The aim of the present study was to compare the anti-leukemic effects of Glivec™ (a commercial IM) and its generic formulation, OHK9511. The IC50 values of OHK9511 and Glivec™ were comparable, and both induced similar levels of apoptosis in several CML cell lines. Furthermore, the overall survival of OHK9511-treated mice transplanted with BCR-ABL-positive cells was similar to that of mice treated with Glivec™. Although the experiments performed herein were basic, the results suggest that...Continue Reading

References

Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A HahnUNKNOWN IRIS Investigators
Feb 8, 2008·Blood·Richard A LarsonUNKNOWN IRIS (International Randomized Interferon vs STI571) Study Group
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoko TabeMark Raffeld
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinJamshid S Khorashad
Mar 23, 2011·Journal of the National Cancer Institute·Carlo Gambacorti-PasseriniDong-Wook Kim
May 27, 2011·The New England Journal of Medicine·Thomas J Smith, Bruce E Hillner
Jun 5, 2012·International Journal of Hematology·Peter Rohon
Dec 25, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stacie B DusetzinaNancy L Keating
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis